Ionis to present at upcoming investor conferences

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:

  • 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025
  • H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025
  • Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025

A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events-and-presentations/upcoming-events. Replays will be available on the Ionis website within 48 hours and will be archived for a limited time.

About Ionis Pharmaceuticals

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.

Contacts

Ionis Pharmaceuticals Investor Contact:

D. Wade Walke, Ph.D. – ir@ionis.com760-603-2331

Ionis Pharmaceuticals Media Contact:

Hayley Soffer – media@ionis.com – 760-603-4679

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  234.69
-2.89 (-1.22%)
AAPL  272.41
-0.54 (-0.20%)
AMD  246.81
-1.15 (-0.46%)
BAC  52.61
-0.26 (-0.49%)
GOOG  276.98
-2.14 (-0.77%)
META  609.46
-0.43 (-0.07%)
MSFT  510.18
+6.89 (1.37%)
NVDA  190.17
+3.31 (1.77%)
ORCL  222.85
+5.28 (2.43%)
TSLA  404.35
+2.36 (0.59%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.